The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide.

智通财经获悉，美国食品和药物管理局(FDA)周一批准了Hikma仿制诺和诺德(NVO.US)糖尿病药物Victoza，为该药物的另一种仿制药在美国上市扫清了道路。Hikma的品牌仿制药将与Teva制药公司竞争，Teva制药公司今年早些时候在美国推出了 ...

Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

智通财经获悉，美国食品和药物管理局(FDA)周一批准了Hikma仿制诺和诺德(NVO.US)糖尿病药物Victoza，为该药物的另一种仿制药在美国上市扫清了道路。

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

【FDA批准首个用于治疗低血糖的GLP-1仿制药】财联社12月24日电，美国食品药品管理局（FDA）批准首个用于治疗低血糖的GLP-1仿制药。 批准首个提及VICTOZA的仿制药。 适用于改善糖尿病患者的血糖控制。

Generic Victoza is a GLP-1 receptor agonist indicated to improve glycemic control in adults and pediatric patients aged 10 ...

The U.S. Food and Drug Administration (FDA) has approved a generic daily injectable for the GLP-1 medication for patients who ...

The U.S. Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmac ...

The first generic of the first-generation obesity treatment has been approved in the United States. The U.S. Food and Drug ...